ELTX

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA. Wells Fargo 21st Annual Healthcare ConferenceFormat: One-on-one MeetingsDate: Thursday, September 10, 2026 If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative. About Elicio Therapeutics Elicio Therapeutics, Inc.

10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026 While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma ("PDAC")Memorial Sloan Kettering Cancer Center-led Phase 1 trial activated evaluating ELI-002 7P plus chemotherapy and checkpoint inhibition with treat

Phase 1 study conducted by Memorial Sloan Kettering ("MSK") Cancer Center and funded by The Lustgarten FoundationStudy to evaluate ELI-002 7P in combination with chemotherapy and checkpoint inhibition in the neoadjuvant settingExpected to enroll 20 patients with resectable or borderline resectable pancreatic ductal adenocarcinoma ("PDAC") BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the opening of the investigator-initiated ("IIT") Phase 1 neoadjuvant study (NCT07671339) evaluating ELI-002 7P in combin

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

SCHEDULE 13G/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the closing of its previously announced registered direct offering (the "Offering") pursuant to a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock. The gross proceeds to the Company were approximately $15 million, before deducting placement agents’ fees and other Offering expenses. Elicio inten

424B5 - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registered direct offering (the "Offering"). The Offering is expected to result in gross proceeds of approximately $15 million, before deducting placement agents’ fees and other Offering expenses. The clos

BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution. "Inclusion of Elicio Therapeutics in the Russell 2000® and Russell 3000® Indexes is a meaningful milestone that reflects the growing recognition of the Company’s progress," said Robert Connelly, Chief Executive Officer of Elicio Therapeutics. "As we continue to advance our

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

Ladenburg Thalmann resumed coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $12.00

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapyComplete responses ("CRs") are rarely (0-8%) observed in metastatic pancreatic cancer in published studies evaluating chemotherapy-, checkpoint inhibitor-, and RAS inhibitor-based regimensELI-002 7P-induced mutant KRAS("mKRAS")-specific T cells may synergize with checkpoint inhibition to allow deep antitumor responses in a tumor type previously considered refractory to immunotherapyElicio believes these post-study observations build on mechanistic validation from prior AMPLIFY studies

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival ("DFS") in the intent-to-treat population.Randomization balanced most prognostic factors between arms. However, the ELI-002 7P arm had a higher proportion of R1 resected (higher residual disease, tumor present at or within 1 mm of surgical margin) patients compared with the observation arm (ELI-002 7P 19% vs. observation 10%), a known adverse prognostic factor for recurrence.  R1 patients have increased relapse-risk, implying that this imbalance meaningfully and negatively impacted the ELI-002 arm.Post-hoc analysis identified a stronger DFS hazard ratio in the R0, completely resected population (post-hoc HR 0

B. Riley Securities initiated coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $27.00

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of a peer-reviewed manuscript in Science Advances, published by the American Association for the Advancement of Science, describing a series of novel AMP-DNA adjuvant candidates built from the lymph node-targeting Amphiphile ("AMP") platform technology.   The manuscript, titled "Lymph node targeted DNA engages TBK1/IFN-I driven innate immunity to induce potent T cell responses and durable memory in mice and NHPs," highlights the abilit

10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)